Reversal of resistance by GF120918 in cell lines expressing the ABC half-transporter, MXR

Cancer Letters

Volumn 146, Issue 2, 1999, Pages 117-126

  De Bruin, Michiel ^a   Miyake, Keisuke ^a   Litman, Thomas ^a   Robey, Robert ^a   Bates, Susan E ^a  

^a Division of Clinical Sciences   (United States)

Author keywords

GF120918; Mitoxantrone; Multidrug resistance; MXR; P glycoprotein

Indexed keywords

ABC TRANSPORTER; ANTIINFECTIVE AGENT; ELACRIDAR; GLYCOPROTEIN P; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN; RHODAMINE; TOPOTECAN; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL; CELL STRAIN MCF 7; COLON CANCER; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACCUMULATION; DRUG RESISTANCE; FLOW CYTOMETRY; FLUORESCENCE; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

ACRIDINES; ATP-BINDING CASSETTE TRANSPORTERS; CALCIUM; DRUG RESISTANCE, MULTIPLE; HUMANS; ISOQUINOLINES; MICROSCOPY, CONFOCAL; MITOXANTRONE; RHODAMINES; TETRAHYDROISOQUINOLINES; TUMOR CELLS, CULTURED;

MINK CELL FOCUS-FORMING VIRUS;

EID: 0032695270     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(99)00182-2     Document Type: Article

References (29)

1. Gottesman M.M., Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem. 62:1993;385-427.
2. Loe D.W., Deeley R.G., Cole S.P. Biology of the multidrug resistance-associated protein, MRP. Eur. J. Cancer, 32A. 1996;945-957.
3. Koike K., Kawabe T., Tanaka T., Toh S., Uchiumi T., Wada M., Akiyama S., Ono M., Kuwano M. A canalicular multispecific organic anion transporter (cMOAT) cDNA enhances drug sensitivity in human hepatic cancer cells. Cancer Res. 57:1997;5475-5479.
4. Kool M., de Haas M., Scheffer G.L., Scheper R.J., van Eijk M.J., Juijn J.A., Baas F., Borst P. Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene in human cancer cell lines. Cancer Res. 57:1997;3537-3547.
5. Lee K., Belinsky M.G., Bell D.W., Testa J.R., Kruh G.D. Isolation of MOAT-B, a widely expressed multidrug resistance-associated protein/canalicular multispecific organic anion transporter-related transporter. Cancer Res. 58:1998;2741-2747.
6. Allikmets R., Gerrard B., Hutchinson A., Dean M. Characterization of the human ABC superfamily: isolation and mapping of 21 new genes using the expressed sequence tags database. Hum. Mol. Genet. 5:1996;1649-1655.
7. Doyle L.A., Yang W., Abruzzo L.V., Krogmann T., Gao Y., Rishi A.K., Ross D.D. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc. Natl. Acad. Sci. USA. 95:1998;15665-15670.
8. Miyake K., Mickley L., Litman T., Zhan Z., Robey R., Cristensen B., Brangi M., Greenberger L., Dean M., Fojo T., Bates S.E. Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes. Cancer Res. 59:1999;8-13.
9. Allikmets R., Schriml L.M., Hutchinson A., Romano-Spica V., Dean M. A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. Cancer Res. 58:1998;5337-5339.
10. Croop J.M., Tiller G.E., Fletcher J.A., Lux M.L., Raab E., Goldenson D., Son D., Arciniegas S., Wu R.L. Isolation and characterization of a mammalian homolog of the Drosophila white gene. Gene. 185:1997;77-85.
11. Ewart G.D., Howells A.J. ABC transporters involved in transport of eye pigment precursors in Drosphila melanogaster. Methods Enzymol. 292:1998;213-224.
12. Tew K.D., Houghton P.J., Houghton J.A. Modulation of P-glycoprotein-mediated drug resistance in preclinical and clinical modulation of anticancer drugs. Cancer. 1993;125-196.
13. Ferry D.R., Traunecker H., Kerr D.J. Clinical trials of P-glycoprotein reversal in solid tumours. Eur. J. Cancer, 32A. 1996;1070-1081.
14. Sandor V., Fojo T., Bates S.E. Future perspectives for the development of P-glycoprotein modulators. Drug Resistance Updates. 1:1998;190-200.
15. Boer R., Gekeler V. Chemosensitizers in tumor therapy: new compounds promise better efficacy. Drugs Future. 20:1995;499-509.
16. den Ouden D., van den Heuvel M., Schoester M., van Rens G., Sonneveld P. In vitro effect of GF120918, a novel reversal agent of multidrug resistance, on acute leukemia and multiple myeloma cells. Leukemia. 10:1996;1930-1936.
17. Zhou D.C., Simonin G., Faussat A.M., Zittoun R., Marie J.P. Effect of the multidrug inhibitor GG918 on drug sensitivity of human leukemic cells. Leukemia. 11:1997;1516-1522.
18. Zhang X.P., Ritke M.K., Yalowich J.C., Slovak M.L., Ho J.P., Collins K.I., Annable T., Arceci R.J., Durr F.E., Greenberger L.M. P-glycoprotein mediates profound resistance to bisantrene. Oncol. Res. 6:1994;291-301.
19. Rabindran S.K., He H., Singh M., Brown E., Collins K.I., Annable T., Greenberger L.M. Reversal of a novel multidrug resistance mechanism in human colon carcinoma cells by fumitremorgin C. Cancer Res. 58:1998;5850-5858.
20. Schneider E., Horton J.K., Yang C.H., Nakagawa M., Cowan K.H. Multidrug resistance-associated protein gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF7 cell line selected for etoposide resistance. Cancer Res. 54:1994;152-158.
21. Skehan P., Storeng R., Scudiero D., Monks A., McMahon J., Vistica D., Warren J.T., Bokesch H., Kenney S., Boyd M.R. New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst. 82:1990;1107-1112.
22. Lee J.S., Paull K., Alvarez M., Hose C., Monks A., Grever M., Fojo A.T., Bates S.E. Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute Drug Screen. Mol. Pharmacol. 46:1994;627-638.
23. Versantvoort C.H., Bagrij T., Wright K.A., Twentyman P.R. On the relationship between the probenecid-sensitive transport of daunorubicin or calcein and the glutathione status of cells overexpressing the multidrug resistance-associated protein (MRP). Int. J. Cancer. 63:1995;855-862.
24. Germann U.A., Ford P.J., Shlyakhter D., Mason V.S., Harding M.W. Chemosensitization and drug accumulation effects of VX-710, cyclosporin A, MS-209 and GF120918 in multidrug resistant HL60/ADR cells expressing the multidrug resistance-associated protein MRP. Anticancer Drugs. 8:1997;141-155.
25. Lee J.S., Scala S., Matsumoto Y., Dickstein B., Robey R., Zhan Z., Altenberg G., Bates S.E. Reduced drug accumulation and multidrug resistance in human breast cancer cells without associated P-glycoprotein or MRP overexpression. J. Cell Biochem. 65:1997;513-526.
26. Feller N., Broxterman H.J., Wahrer D.C., Pinedo H.M. ATP-dependent efflux of calcein by the multidrug resistance protein (MRP): no inhibition by intracellular glutathione depletion. FEBS Lett. 368:1995;385-388.
27. Dietel M., Arps H., Lage H., Niendorf A. Membrane vesicle formation due to acquired mitoxantrone resistance in human gastric carcinoma cell line EPG85-257. Cancer Res. 50:1990;6100-6106.
28. Witherspoon S.M., Emerson D.L., Kerr B.M., Lloyd T.L., Dalton W.S., Wissel P.S. Flow cytometric assay of modulation of P-glycoprotein function in whole blood by the multidrug resistance inhibitor GG918. Clin. Cancer Res. 2:1996;7-12.
29. Ling V. Multidrug resistance: molecular mechanisms and clinical relevance. Cancer Chemother. Pharmacol. 40:1997;S3-S8.